News from the Innovative Medicines for Tuberculosis Foundation
26 Jun 2018 – PBTZ169 has been named Macozinone. Read more here.
16 Mar 2018 – The first three investigation panels of the Phase Ia clinical trial have been successfully completed. The fourth and final panel has started and healthy male volunteer recruitment is complete.
01 Jan 2018 – Dr. Stewart Cole, Chair of the iM4TB Foundation board and co-founder named head of illustrious Institut Pasteur
01 Jan 2018 – The Year in Review, what happened at iM4TB in 2017
05 Dec 2017 – Start of Phase Ia clinical trial with single ascending dose The trial is divided into 4 investigation panels.
01 Nov 2015 – Dr Antonia Di Micco joins the Foundation iM4TB for 6 months to help preparing Regulatory documents required for the submission of a Clinical Trial Application for a clinical study with PBTZ 169 next year
19 January 2015 – Prof. Stewart Cole elected to French National Academy of Pharmacy
Media coverage – Print
Financial Times – Genetics offers route to cure tuberculosis
Medical Press – New and extremely promising antibiotic for tuberculosis
Drug Discovery & Development – New TB antibiotic help kill multi-resistant strains
Media coverage – Audio/video
RTS – Radio Télévision Suisse – Tuberculose – histoire évolutive et bactérie zombie (in french)
RTS – Radio Télévision Suisse – L’histoire de certaines épidémies serait liée à certains grands événements politiques (in french)
WRG World Radio Geneva – listen to interview
RTS – Radio Télévision Suisse – listen to interview (in french)
La Télé – Swiss Regional Television – watch broadcast interview (in french)
RSR – Radio Suisse Romande – listen to interview (in french)